Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: Limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients-Reference-Cited by-同舟云学术

Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: Limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients

Published:1994-08-01 Issue:3 Volume:58 Page:330-339
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Mazzocchi Arabella,Belli Filiberto,Mascheroni Luigi,Vegetti Claudia,Parmiani Giorgio,Anichini Andrea

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference30 articles.

1. Clonal analysis of the cytolytic T-cell response to human tumors

2. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.

3. , , , , and , Melanocyte lineage-specific antigen gp100 is recognized by melanoma-de rived tumor-infiltrating lymphocytes. J. exp. Med. (1994) (In press).

4. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency determination of breast tumor-reactive CD4 and CD8 T cells in humans: unveiling the antitumor immune response;OncoImmunology;2019-05-15

2. Estimating Point and Interval Frequency of Antigen-Specific CD4+ T Cells Based on Short In Vitro Expansion and Improved Poisson Distribution Analysis;PLoS ONE;2012-08-07

3. Antigen-specific versus Antigen-nonspecific Immunotherapeutic Approaches for Human Melanoma: The Need for Integration for Optimal Efficacy?;International Reviews of Immunology;2011-11-07

4. Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance;Immunotherapy;2011-10

5. Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines;Cancers;2011-07-18